[
  {
    "title": "Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million",
    "link": "https://www.globenewswire.com/news-release/2026/02/21/3242195/0/en/Rakovina-Therapeutics-Announces-Upsized-Financing-Up-to-2-0-Million.html",
    "description": "<p align=\"center\"><em>Proposed $1.0 Million Convertible Debenture and Warrant Financing and\u00a0</em><br><em>Concurrent Common Share Private Placement Up to $1.0 Million </em><br><em>Intended to Support Near-Term Operations</em></p>",
    "pubDate": "Sat, 21 Feb 2026 00:50 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Fortera",
      "Asimov",
      "Profluent"
    ],
    "categories": [
      "funding",
      "product"
    ]
  },
  {
    "title": "K2 Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on February 25, 2026  \u00a0",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242185/0/en/K2-Capital-Acquisition-Corp-Announces-the-Separate-Trading-of-its-Class-A-Ordinary-Shares-and-Rights-Commencing-on-February-25-2026.html",
    "description": "<p align=\"justify\">NEW YORK, Feb.  20, 2026  (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corp. (the \"Company\") today announced that, commencing on February 25, 2026, holders of the 13,800,000 units (the \u201cUnits\u201d) sold in the Company\u2019s initial public offering (the \u201cOffering\u201d), including Units sold upon full exercise of the underwriters\u2019 over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on",
    "pubDate": "Fri, 20 Feb 2026 23:00 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Flexport"
    ],
    "categories": [
      "product",
      "ipo"
    ]
  },
  {
    "title": "Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242180/0/en/Psyence-BioMed-Announces-Exercise-of-Put-Option-by-PsyLabs-and-Strategic-Equity-Investment.html",
    "description": "<p align=\"justify\">NEW YORK, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201c<strong>Psyence BioMed</strong>\u201d or the \u201c<strong>Company</strong>\u201d), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (\"<strong>PsyLabs</strong>\") has exercised its rights under a previously disclosed pu",
    "pubDate": "Fri, 20 Feb 2026 22:20 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Zipline",
      "Kinova Robotics"
    ],
    "categories": [
      "funding",
      "product"
    ]
  },
  {
    "title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242177/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html",
    "description": "<p>SAN CARLOS, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (\"Iovance\" or the \u201cCompany\u201d), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (\u201cTIL\u201d) therapies for patients with cancer, today announced that on February 19, 2026 (the \u201cDate of Grant\u201d), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance\u2019s common stock to two new, n",
    "pubDate": "Fri, 20 Feb 2026 22:15 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Focused Energy",
      "Fortera",
      "Asimov",
      "Profluent"
    ],
    "categories": []
  },
  {
    "title": "Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares ",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242170/8624/en/Trinity-Biotech-Receives-Non-Compliance-Notice-Regarding-Nasdaq-Global-Select-Requirement-for-Minimum-Market-Value-of-Publicly-Held-Shares.html",
    "description": "<p align=\"justify\">DUBLIN, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (\u201cMVPHS\u201d) of $15,000,000,",
    "pubDate": "Fri, 20 Feb 2026 22:00 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Mammoth Biosciences",
      "Focused Energy",
      "Tempus AI",
      "Oxford Nanopore Technologies",
      "Neko Health"
    ],
    "categories": [
      "ipo"
    ]
  },
  {
    "title": "Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242156/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html",
    "description": "<p align=\"left\">NOVATO, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 22,917 restricted stock units of the company\u2019s common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company\u2019s board of directors and granted under ",
    "pubDate": "Fri, 20 Feb 2026 21:30 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Focused Energy",
      "Fortera"
    ],
    "categories": [
      "contract",
      "hiring"
    ]
  },
  {
    "title": "iPower Reports Fiscal Q2 2026 Results and Completes Strategic Operating Reset",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242159/0/en/iPower-Reports-Fiscal-Q2-2026-Results-and-Completes-Strategic-Operating-Reset.html",
    "description": "<p align=\"justify\">RANCHO CUCAMONGA, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (\u201ciPower\u201d or the \u201cCompany\u201d) today reported financial results for the fiscal second quarter ended December 31, 2025. Revenue was <strong>$7.1 million</strong>, reflecting the Company\u2019s <strong>deliberate supply chain restructuring and transition to predominantly U.S.-based sourcing during the quarter</strong>, while gross profit was <strong>$3.1 million</strong> and gross margin remained str",
    "pubDate": "Fri, 20 Feb 2026 21:30 GMT",
    "source": "globenewswire_all",
    "companies": [
      "The Boring Company",
      "Bronco AI",
      "Fortastra"
    ],
    "categories": [
      "funding",
      "milestone",
      "ipo"
    ]
  },
  {
    "title": "Xanadu to Host Analyst Day on March 4, 2026",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242161/0/en/Xanadu-to-Host-Analyst-Day-on-March-4-2026.html",
    "description": "<p>TORONTO, Feb.  20, 2026  (GLOBE NEWSWIRE) -- Xanadu Quantum Technologies Inc. (\u201cXanadu\u201d), a leading photonic quantum computing company, today announced that it will host an Analyst Day on Wednesday, March 4, 2026 at 9:00 am ET<strong>.</strong></p>",
    "pubDate": "Fri, 20 Feb 2026 21:30 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Rocket Lab",
      "Atom Computing",
      "Conductor Quantum",
      "PsiQuantum",
      "IonQ",
      "Rigetti Computing",
      "QuEra Computing",
      "Oxford Quantum Circuits",
      "planqc",
      "Pasqal",
      "Alice & Bob",
      "IQM Quantum Computers",
      "QuantWare",
      "Quantum Machines",
      "Xanadu Quantum Technologies",
      "Quantum Brilliance",
      "D-Wave Quantum",
      "Photonic Inc",
      "Nord Quantique",
      "Q-CTRL",
      "Quantinuum",
      "QuiX Quantum"
    ],
    "categories": []
  },
  {
    "title": "Electra Upsizes At-The-Market Offering",
    "link": "https://www.globenewswire.com/news-release/2026/02/20/3242154/0/en/Electra-Upsizes-At-The-Market-Offering.html",
    "description": "<p align=\"justify\">TORONTO, Feb.  20, 2026  (GLOBE NEWSWIRE) -- <strong>Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM)</strong> (\u201cElectra\u201d or the \u201cCompany\u201d) has announced that it has upsized its previously announced At the Market Offering Program (the \u201cATM\u201d), pursuant to which the Company may offer and sell, at its discretion and from time to time, through H.C. Wainwright & Co., LLC (\u201cWainwright\u201d), common shares in the capital of the Company (the \u201cCommon Shares\u201d) having an",
    "pubDate": "Fri, 20 Feb 2026 21:20 GMT",
    "source": "globenewswire_all",
    "companies": [
      "Impulse Labs",
      "Space Forge"
    ],
    "categories": []
  }
]